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OBJECTIVES: Payers are increasingly concerned with assessing the value of 
pharmaceutical products to guide reimbursement and pricing decisions, and 
particularly in countries employing an HTA process, value is often largely based 
on clinical effectiveness measured as cost-per-QALY. The objective of this study 
is to assess how the EQ-5D index reacts across a broad range of conditions to 
clinical changes which are considered significant at the individual disease and 
patient level. METHODS: A systematic review of published studies assessing the 
psychometric properties of the EQ-5D, in particular studies reporting statistics on 
the responsiveness of the EQ-5D index. The Standardised Response Mean (SRM) 
and Effect Size (ES), which are both measures of signal-to-noise and describe the 
responsiveness of EQ-5D to clinical change, are compared to benchmark scores 
from the psychometric literature. We also compare the Visual Analogue Scale (VAS) 
self-reported health component against the EQ-5D index. RESULTS: In the majority 
of studies, the responsiveness of EQ-5D to clinical change overall was poor to 
moderate: In only approx. half of studies was the VAS score within 10% of the EQ-
5D index score. Ceiling effects of >15% at baseline where reported in half the studies 
examined. Only 25% of studies reported ES values within the range considered 
“moderate” to “good”, and 7% of studies reported SRM values in the “moderate” to 
“good” range. CONCLUSIONS: When considering widely accepted psychometric 
benchmarks and the relation between self-reported health and EQ-5D index, only a 
minority of studies (11%) report consistently good performance of the EQ-5D in 
reflecting clinically important changes. Consequently, a significant proportion of 
therapeutic value (both from a clinical and patient perspective) is not adequately 
captured by the existing EQ-5D framework. This has implications for the way new 
therapies have traditionally been assessed for value, particular as countries start 
moving towards value based pricing.  
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OBJECTIVES: The use of financial incentives and disincentives is being explored 
as a way to encourage people to adopt healthier lifestyles. However, published 
methodological research in this area is limited. The objective was to explore the 
acceptability and pricing of incentives in NHS patients. METHODS: A contingent 
valuation survey was completed by patients who recently had a (confirmed or 
suspected) cardiac event and who either smoked, were overweight, physically 
inactive or abused alcohol. Respondents completed questions on health 
behaviour, perceived difficulty of behaviour change, minimum incentive 
required to motivate behaviour change along with attitudinal questions 
(incentive acceptability, motivation, perceived risk) and items on income and 
time preference. RESULTS: The survey was completed by 132 patients (39% 
Female; Mean age=59). A majority - 65% - did not agree that incentives should be 
offered by the NHS. There was a trend for males (p=.064) and higher income 
groups (p=.026) to be less in favour of incentives. Mean incentive levels required 
to help stop smoking, lose weight, exercise and reduce alcohol consumption 
were £88, £46, £57 and £30 per month, respectively. This represented 11%, 6%, 
10% and 4% of monthly household income, respectively. The minimum required 
incentive increased with higher levels of perceived change difficulty and 
decreased with higher reported motivation to change. Mean incentive levels 
required to stop smoking were: £18, £43 and £116; and for weight loss: £25, £53, 
and £62 for those perceiving change as easy, moderate and difficult, respectively. 
CONCLUSIONS: This preliminary analysis is one of the few to provide incentive 
pricing data and may prove useful in designing future incentive schemes. Incentive 
schemes may need to be targeted to the individual, taking into account (inter alia) 
their income, perceived difficulty of change and motivation levels. Future studies 
should explore targeted incentive pricing strategies on behaviour change.  
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OBJECTIVES: Medication access due to lack of affordability remains an issue in 
many Latin American countries. “The Generic Law” enacted in Argentina in 2002 
mandated that all prescribers write prescriptions with the active ingredient 
(International Nonproprietary Name, INN) instead of brand names. This study 
determined the effects of this policy on drug pricing in Argentina by comparing 
price and utilization trends of brand and generic drugs pre- and post-policy 
implementation. METHODS: Analyses included IMS data of annual WHO 
essential drug prices in Argentina from 1995-2010 and exclude those drugs with 
fewer than 4 years of price data. We compared generic and brand average annual 
price trends before and after policy implementation for 32 essential drugs, 
accounting for inflation resulting from an economic crisis in the year before the 
policy took effect. RESULTS: While actual price still increased, there was a 
decreased rate of change immediately after the policy change in both generic 
and brands of 22 drugs. Ten drugs did not exhibit the expected decrease in price 
trend; mainly antibiotics or drugs with a market competition of less than 10 or 
greater than 30 generic products. Available utilization data showed demand 
decreased as price rose, depending on market competition. CONCLUSIONS: In 
the years following implementation of The Generic Law, the rate of price change 
decreased for both brand and generic drugs. This research provides evidence to 
support the effectiveness of the generic policy in Argentina in controlling out-of-
pocket expenditure increases for medication. However, since this policy was 
enacted under specific market conditions, additional research must be 
conducted in other countries with a generic policy to confirm the observed 
outcomes.  
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Anticoagulant treatment is the mainstay for stroke prevention in atrial 
fibrillation (AF); however, the increased risk of bleeding caused by anticoagulants 
requires considering benefit-risk tradeoffs in their use. Patient and physician 
preferences for avoiding death, stroke and bleeding underlie these 
considerations and influence treatment decisions. OBJECTIVES: To quantify and 
compare US patient and physician preferences for benefits and risks associated 
with anticoagulants in AF. METHODS: Adult patients with a self-reported 
physician diagnosis of AF, and board-certified internists or cardiologists treating 
AF patients, completed a web-based, choice-format conjoint survey. Tradeoff 
questions in the survey included a pair of hypothetical anticoagulants defined by 
a risk profile including disabling and non-disabling stroke, myocardial infarction, 
embolism, and major and non-major clinically-relevant bleeding. Patients chose 
anticoagulants for themselves, while physicians chose anticoagulants for virtual 
patients. Random-parameters logit was used to estimate relative preference 
weights for the likelihood of experiencing outcomes. RESULTS: 186 patients 
(mean age 65.6) and 107 physicians completed the survey. Patients considered 
disabling stroke as the least desirable outcome, while physicians regarded death 
as least desirable. Relative to the risk of disabling stroke, patients considered 
death 60% (95% CI 39%-80%) as important, and non-fatal major bleeding and 
non-major clinically-relevant bleeding 47% (28%-65%) and 17% (10%-23%) as 
important, respectively. For physicians, relative to the risk of disabling stroke, 
death was 150% (82%-218%) as important, and non-fatal major bleeding and non-
major clinically-relevant bleeding were 66% (47%-84%) and 14% (8%-20%) as 
important. Non-fatal embolism and myocardial infarction were of intermediate 
importance between the two levels of bleeding for both groups. CONCLUSIONS: 
US patient decisions on anticoagulant treatment in AF may be more motivated 
by avoiding strokes, while physicians may focus more on avoiding death. The 
difference in perspective on relative importance of bleeding and stroke may lead 
to different benefit-risk assessments by patients and physicians.  
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OBJECTIVES: Heart failure (HF) is associated with increased risk of dementia and 
dementia is an independent predictor of mortality and hospitalization in HF 
patients. Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin 
receptor blockers (ARBs) may lower the risk of dementia by regulating the renin 
angiotensin system in the brain. Given the significant clinical impact of 
dementia associated with HF and the current urgency for effective treatments to 
reduce the incidence of dementia, the present study examines the effectiveness 
of ACEIs/ARBs that are widely prescribed for the treatment of HF. METHODS: 
This retrospective, longitudinal study used a cohort of patients with HF 
identified from a local Medicare advantage prescription drug plan to examine 
incidence of dementia with up to 3 years of follow up period. Multivariable time 
dependent Cox model and inverse-probability-of-treatment weighting (IPTW) of 
marginal structural model were used to estimate the risk of developing dementia 
controlling for sociodemographic factors, comorbidities, comedications, 
appropriate laboratory measures, and potential time-varying confounding 
affected by previous treatment (hospitalization). Adjusted dementia rate ratios 
were estimated among current and former ACEI/ARB users, as compared with 
nonusers. RESULTS: The study included a total of 8062 HF patients (mean age 
74.47 ±9.21 years) of which 1135 (14.08 %) patients were diagnosed with dementia 
during the median follow up of 22 months. Using the time dependent Cox model, 
the adjusted dementia rate ratios (95% confidence interval) among current and 
former users were 0.90 (0.70 - 1.16) and 0.89 (0.71 - 1.10). Use of IPTW resulted in 
similar effect estimates (95% conservative confidence interval) of 0.99 (0.74 - 1.32) 
among current users and 0.80 (0.59 - 1.08) for former users as compared with the 
nonusers. CONCLUSIONS: This study found no difference in risk of dementia 
among the current and former users of ACEI/ARB as compared with the nonusers 
in an already at-risk HF population.  
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OBJECTIVES: Both increased age and type-2 diabetes are risk factors for 
developing bone fractures. While recent data in elderly diabetic individuals 
suggest a link between hypoglycemia and elevated risk of fall-related fractures, 
the association between sulfonylureas (SU), commonly used hypoglycemic 
agents, and fracture risk is not well investigated. METHODS: We conducted a 
study to evaluate the association between SU and risk of developing hip fracture 
